Characteristics | Total | BMIhisto+ | BMIhisto– | P value* |
---|---|---|---|---|
 | (n = 1585) | (n = 259) | (n = 1326) |  |
Median age, years (range) | 57.4 (1.9-90.9) | 59.0 (1.9-86.4) | 57.0 (5.3-90.9) | 0.013 |
Age > 60Â yr | 679/1585 (42.8) | 124/259 (47.9) | 555/1326 (41.9) | 0.073 |
Gender (male/female, %male) | 881/704 (55.6) | 132/127 (51.0) | 749/577 (56.5) | 0.102 |
B symptoms | 394/1585 (24.9) | 135/259 (52.1) | 259/1326 (19.5) | <0.001 |
ECOG ≥ 2 | 226/1585 (14.3) | 86/259 (33.2) | 140/1326 (10.6) | <0.001 |
High serum LDH | 975/1585 (61.5) | 203/259 (78.4) | 772/1326 (58.2) | <0.001 |
Stage 3 or 4 | 822/1585 (52.6) | 259/259 (100) | 574/1326 (43.3) | <0.001 |
Stage 3 or 4, excluding BM status | 809/1585 (51.0) | 237/259 (91.5) | 572/1326 (43.1) | <0.001 |
Extranodal involvement ≥ 2 sites | 497/1585 (31.4) | 193/259 (74.5) | 304/1326 (22.9) | <0.001 |
International Prognostic Index | Â | Â | Â | Â |
  Low risk | 392/1585 (24.7) | 0/259 (0) | 392/1326 (29.6) | <0.001 |
  Low/intermediate risk | 462/1585 (29.2) | 33/259 (12.7) | 427/1326 (32.4) |  |
  High/intermediate risk | 467/1585 (29.5) | 114/259 (44.0) | 353/1326 (26.6) |  |
  High risk | 264/1585 (16.7) | 112/259 (43.2) | 152/1315 (11.5) |  |
Non-GCB type | 500/877 (57.0) | 95/150 (63.3) | 405/727 (55.7) | 0.086 |
CD5-positive | 33/341 (9.7) | 7/57 (12.3) | 26/284 (9.2) | 0.466 |
Initial treatment | Â | Â | Â | Â |
  R-CHOP | 1128/1585 (71.2) | 146/259 (56.4) | 982/1326 (74.1) | <0.001 |
  CHOP | 157/1585 (9.9) | 30/259 (11.6) | 127/1326 (9.6) |  |
  Other treatment | 223/1585 (14.1) | 53/259 (20.5) | 170/1326 (12.8) |  |
  No therapy | 77/1585 (4.9) | 30/259 (11.6) | 47/1326 (3.5) |  |
Initial treatment response | Â | Â | Â | Â |
  CR | 1020/1394 (73.2) | 118/207 (57.0) | 902/1187 (76.0) | <0.001 |
  PR | 268/1394 (19.2) | 51/207 (24.6) | 217/1187 (18.3) |  |
  SD | 33/1394 (2.4) | 8/207 (3.9) | 25/1187 (2.1) |  |
  PD | 73/1394 (5.2) | 30/207 (14.5) | 43/1187 (3.6) |  |
Follow-up data | Â | Â | Â | Â |
  Deaths | 484/1585 (30.5) | 134/259 (51.7) | 350/1326 (26.4) | <0.001 |
  Median follow-up, months (range) | 25.7 (0.1-211.1) | 12.0 (0.1-141.4) | 29.5 (0.1-211.1) | <0.001 |